Skip to main content
Article
The adipose tissue production of adiponectin is increased in end-stage renal disease.
Department of Medicine Faculty Papers
  • Maria P Martinez Cantarin, Thomas Jefferson University, Clinical Pharmacology and Experimental Therapeutics; Department of Medicine, Thomas Jefferson University
  • Scott A Waldman, Thomas Jefferson University, Clinical Pharmacology and Experimental Therapeutics
  • Cataldo Doria, Department of Surgery, Thomas Jefferson University
  • Adam M Frank, Department of Surgery, Thomas Jefferson University
  • Warren R Maley, Department of Surgery, Thomas Jefferson University
  • Carlo B Ramirez, Department of Surgery, Thomas Jefferson University
  • Scott W Keith, Thomas Jefferson University, Clinical Pharmacology and Experimental Therapeutics
  • Bonita Falkner, Department of Medicine, Thomas Jefferson University
Document Type
Article
Publication Date
3-1-2013
Disciplines
Comments
This article has been peer reviewed. It was published in: Kidney International.
Volume 83, Issue 3, March 2013, Pages 487-494.
The published version is available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3587362/. DOI: 10.1038/ki.2012.421

Copyright ©2012 International Society of Nephrology.
Abstract

Adiponectin has antidiabetic properties, and patients with obesity, diabetes, and insulin resistance have low plasma adiponectin levels. However, although kidney disease is associated with insulin resistance, adiponectin is elevated in end-stage renal disease. Here we determine whether adipose tissue production of adiponectin is increased in renal disease in a case-control study of 36 patients with end-stage renal disease and 23 kidney donors. Blood and tissue samples were obtained at kidney transplantation and donation. The mean plasma adiponectin level was significantly increased to 15.6 mg/ml in cases compared with 8.4 mg/ml in controls. Plasma levels of the inflammatory adipokines tumor necrosis factor α, interleukin 6, and high-sensitivity C-reactive protein were significantly higher in cases compared with controls. Adiponectin mRNA and protein expression in visceral and subcutaneous fat were significantly higher in cases than controls, while adiponectin receptor-1 mRNA expression was significantly increased in peripheral blood cells, muscle, and adipose tissue in cases compared with controls. Thus, our study suggests that adipose tissue production of adiponectin contributes to the high plasma levels seen in end-stage renal disease.

PubMed ID
23283133
Citation Information
Maria P Martinez Cantarin, Scott A Waldman, Cataldo Doria, Adam M Frank, et al.. "The adipose tissue production of adiponectin is increased in end-stage renal disease." (2013)
Available at: http://works.bepress.com/adam_franks/10/